UA65522C2 - Inner cellular isoform of interleukin-1 receptor antagonist - Google Patents

Inner cellular isoform of interleukin-1 receptor antagonist Download PDF

Info

Publication number
UA65522C2
UA65522C2 UA97052129A UA97052129A UA65522C2 UA 65522 C2 UA65522 C2 UA 65522C2 UA 97052129 A UA97052129 A UA 97052129A UA 97052129 A UA97052129 A UA 97052129A UA 65522 C2 UA65522 C2 UA 65522C2
Authority
UA
Ukraine
Prior art keywords
sequence
polypeptide
isi
cells
antagonist
Prior art date
Application number
UA97052129A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of UA65522C2 publication Critical patent/UA65522C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
UA97052129A 1994-10-13 1995-12-10 Inner cellular isoform of interleukin-1 receptor antagonist UA65522C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI942097A IT1270662B (it) 1994-10-13 1994-10-13 Antagonista della interleuchina-1
PCT/EP1995/004023 WO1996012022A1 (en) 1994-10-13 1995-10-12 Intracellular isoform of the interleukin-1 receptor antagonist

Publications (1)

Publication Number Publication Date
UA65522C2 true UA65522C2 (en) 2004-04-15

Family

ID=11369705

Family Applications (1)

Application Number Title Priority Date Filing Date
UA97052129A UA65522C2 (en) 1994-10-13 1995-12-10 Inner cellular isoform of interleukin-1 receptor antagonist

Country Status (18)

Country Link
US (1) US5739282A (de)
EP (1) EP0786002B1 (de)
JP (1) JPH10509306A (de)
KR (1) KR100237936B1 (de)
CN (2) CN100363053C (de)
AT (1) ATE303439T1 (de)
BR (1) BR9509317A (de)
CA (1) CA2202470C (de)
DE (1) DE69534419T2 (de)
EE (1) EE03697B1 (de)
ES (1) ES2243942T3 (de)
IT (1) IT1270662B (de)
MX (1) MX9702616A (de)
NO (1) NO320494B1 (de)
PT (1) PT786002E (de)
RU (1) RU2193064C2 (de)
UA (1) UA65522C2 (de)
WO (1) WO1996012022A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5872095A (en) * 1990-05-01 1999-02-16 Chiron Corporation IL-1 receptor antagonists medicaments
EP0938500B1 (de) * 1996-10-31 2004-09-22 Applied Research Systems ARS Holding N.V. Ice inhibierende peptide
CA2273852C (en) * 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL126562A0 (en) * 1998-10-14 1999-08-17 Interpharm Lab Ltd Expression and secretion of icil-1 receptor antagonist type ii
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US7166712B2 (en) * 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
MX361174B (es) * 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
WO2006014444A1 (en) 2004-07-06 2006-02-09 Zymogenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
RU2326947C2 (ru) * 2004-11-23 2008-06-20 Общество с ограниченной ответственностью "ЦИТОКИН" Способ получения рекомбинантного антагониста рецептора интерлейкина-1 человека "арил"
CA2637166A1 (en) * 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies for treating cancer
US8323635B2 (en) 2007-11-14 2012-12-04 General Regeneratives, Ltd. Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
EP2686431B1 (de) 2011-03-14 2016-08-03 Phlogo ApS Antagonisten des interleukin-1rezeptors
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
CA3119294A1 (en) * 2018-11-15 2020-05-22 Janssen Biotech, Inc. Methods and compositions for prediction of response to a therapy of inflammatory bowel disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148009B1 (ko) * 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
HK1006856A1 (en) * 1989-11-29 1999-03-19 Amgen Inc. Production of recombinant human interleukin-1 inhibitor
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
JPH05506986A (ja) * 1990-05-01 1993-10-14 カイロン コーポレイション インターロイキン―1拮抗物質及びその利用

Also Published As

Publication number Publication date
CN1224707C (zh) 2005-10-26
NO320494B1 (no) 2005-12-12
KR970706391A (ko) 1997-11-03
ITMI942097A1 (it) 1996-04-13
EE9700090A (et) 1997-10-15
WO1996012022A1 (en) 1996-04-25
RU2193064C2 (ru) 2002-11-20
AU701471B2 (en) 1999-01-28
CN1679919A (zh) 2005-10-12
BR9509317A (pt) 1997-10-14
CN100363053C (zh) 2008-01-23
NO971624L (no) 1997-05-30
IT1270662B (it) 1997-05-07
KR100237936B1 (ko) 2000-01-15
EE03697B1 (et) 2002-04-15
CA2202470A1 (en) 1996-04-25
CA2202470C (en) 2008-09-16
PT786002E (pt) 2005-11-30
DE69534419D1 (de) 2005-10-06
HK1002659A1 (en) 1998-09-11
ATE303439T1 (de) 2005-09-15
EP0786002A1 (de) 1997-07-30
MX9702616A (es) 1998-04-30
JPH10509306A (ja) 1998-09-14
HK1081124A1 (zh) 2006-05-12
US5739282A (en) 1998-04-14
CN1161058A (zh) 1997-10-01
ES2243942T3 (es) 2005-12-01
NO971624D0 (no) 1997-04-09
EP0786002B1 (de) 2005-08-31
DE69534419T2 (de) 2006-06-14
ITMI942097A0 (it) 1994-10-13
AU3841795A (en) 1996-05-06

Similar Documents

Publication Publication Date Title
Liu et al. Human junction adhesion molecule regulates tight junction resealing in epithelia
EP0408859B1 (de) Monoklonale Antikörper gegen aktivierte endotheliale Zellen
Pazina et al. Regulation of the functions of natural cytotoxicity receptors by interactions with diverse ligands and alterations in splice variant expression
FI105276B (fi) Diagnostinen järjestelmä, jossa käytetään peptidejä ja vasta-aineita, jotka inhiboivat verihiutaleadheesiota
Schabath et al. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells
Hung et al. Identification of a novel microtubule-destabilizing motif in CPAP that binds to tubulin heterodimers and inhibits microtubule assembly
ES2526079T3 (es) Anticuerpo anti-ILT7
Lin et al. Microtubule actin crosslinking factor 1b: a novel plakin that localizes to the Golgi complex
Honke Biosynthesis and biological function of sulfoglycolipids
Umemoto et al. Nepmucin, a novel HEV sialomucin, mediates L-selectin–dependent lymphocyte rolling and promotes lymphocyte adhesion under flow
UA125717C2 (uk) Конструкція антитіла до flt3 і cd3
Tang et al. Loss of IP3 receptor–mediated Ca2+ release in mouse B cells results in abnormal B cell development and function
EP0786002B1 (de) Intrazelluläre isoform von interleukin-1 rezeptor antagonist
Cai et al. Genome‐wide CRISPR‐Cas9 viability screen reveals genes involved in TNF‐α‐induced apoptosis of human umbilical vein endothelial cells
WO2022117049A1 (zh) Nkg2d car-免疫细胞在抗衰老及老年相关疾病治疗中的应用
Davidson et al. Distribution and immunoregulatory properties of antisecretory factor
Xiao et al. Down‐regulation of L‐type calcium channel in pups born to 52 kDa SSA/Ro immunized rabbits
WO2023143425A1 (zh) 改善认知障碍的方法
US20260102486A1 (en) Use of nkg2d-based cell adapter molecule in removal of aging cells
Chang et al. Characterization of Two EF‐hand Domain‐containing Proteins from Toxoplasma gondii
Navenot et al. Expression of Glycosyl-Phosphatidylinositol-Linked Glycoproteins in Blood Cells from Paroxysmal Nocturnal Haemoglobinuria Patients a Flow Cytometry Study using CD55, CD58 and CD59 Monoclonal Antibodies
Zhou et al. Annexin A2 mediates anti-β2GPI/β2GPI-induced tissue factor expression on monocytes
US9296827B2 (en) Methods and compositions for modulating T cell and/or B cell activation
RU2186783C2 (ru) Кроличья антисыворотка, ингибирующая транспорт катионных аминокислот, и содержащая ее фармацевтическая композиция
CN105968199B (zh) 抗电压门控钾通道1.3胞外环肽段的单克隆抗体及应用